Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Rotigotine skin patch for the treatment of fluctuating Parkinson's disease—how does it compare with pramipexole?

Nature Clinical Practice Neurology volume 3, pages 656–657 (2007)Cite this article

boxed-textPoewe WH et al. (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520

Rotigotine is effective in reducing off time in PD and would be especially beneficial in enhancing patient compliance, in reducing patient tablet load, in patients with dysphagia and in hospitalized patients who cannot take any oral agents

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pahwa R et al. (2006) Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983–995

    Article  CAS  Google Scholar 

  2. Watts RL et al. (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68: 272–276

    Article  CAS  Google Scholar 

  3. LeWitt PA et al. (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68: 1262–1267

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Parkinson Disease and Movement Disorder Center, University of Kansas Medical Center, 3599 Rainbow Boulevard, Kansas City, KS 66160, USA rpahwa@kumc.edu

Authors and Affiliations

  1. R Pahwa is Professor of Neurology and Director of the Parkinson's Disease and Movement Disorder Center at the University of Kansas School of Medicine in Kansas City, KS, USA.,

    Rajesh Pahwa

Authors
  1. Rajesh Pahwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author is a consultant for, and has received research grants and speaker honoraria from, Boehringer Ingelheim (the maker of pramipexole), Schwarz Pharma (the maker of rotigotine), GlaxoSmithKline, Novartis and Teva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pahwa, R. Rotigotine skin patch for the treatment of fluctuating Parkinson's disease—how does it compare with pramipexole?. Nat Rev Neurol 3, 656–657 (2007). https://doi.org/10.1038/ncpneuro0632

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0632

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing